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iLC1s in Tissue inflammation 
and infection
Anja Fuchs*
Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA
Innate lymphoid cells (ILCs) are innate immune cells that provide an early source of cyto-
kines to initiate and tailor the immune response to the type of the encountered pathogen 
or insult. The group 1 ILCs are comprised of conventional natural killer (cNK) cells and 
subsets of “unconventional NK cells,” termed ILC1s. Although cNK cells and ILC1s 
share many features, such as certain phenotypic markers and the ability to produce 
IFN-γ upon activation, it is now becoming apparent that these two subsets develop from 
different progenitors and show unique tissue distribution and functional characteristics. 
Recent studies have aimed at elucidating the individual contributions of cNK cells and 
ILC1s during protective host responses as well as during chronic inflammation. This 
review provides an overview of the current knowledge of the developmental origins as 
well as of the phenotypic and functional characteristics of ILC1s.
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iNTRODUCTiON
Innate lymphoid cells (ILCs) are a recently identified group of cells of the innate immune system that 
modulate immune functions prior to the generation of an adaptive immune response. Unlike T cells 
and B cells, ILCs lack antigen-specific receptors; instead, their function is mediated by cytokines 
released by antigen-presenting cells or damaged tissue cells in response to infection or tissue damage. 
Activated ILCs secrete cytokines that tailor the immune response to the encountered pathogen or 
insult. Based on their secreted cytokine profile, ILCs are regarded as the innate equivalent of adaptive 
T cells: group 1 ILCs are equivalent to Th1 T cells, group 2 ILCs to Th2 T cells, and group 3 ILCs 
to Th17 and Th22 cells (1–4). The group 1 ILCs are comprised of conventional natural killer (cNK) 
cells and several groups of “unconventional NK cells,” termed ILC1s, which differ from conventional 
NK cells in their phenotypes, locations, functions, and/or transcription factor dependence. Within 
group 1 ILCs, cNK cells appear to be more potent in mediating cytotoxicity (“killer ILCs”), while 
the primary role of ILC1s is the production of pro-inflammatory cytokines (“helper-like ILCs”) 
(2). This review will briefly touch on the key features of conventional NK cells as the prototype of 
group 1 ILCs and will then discuss in more detail the known characteristics of the “unconventional 
NK cells,” referred to here as ILC1s. Several subsets of ILC1s have been identified, which are located 
predominantly within non-lymphoid tissues, such as the intestinal mucosa, liver, salivary gland, and 
in the female reproductive tract. For some of the ILC1 subsets, a clear lineage relationship to ILC1s or 
cNK cells has not firmly been established. The paucity of specific surface markers and transcription 
factors for ILC1s has made studying these cells difficult. The ILC field in general is a relatively young 
field of study, and within this field, group 1 ILCs are the least-well studied ILCs compared to ILC2s 
and ILC3s. This review aims at giving an overview of the current knowledge on the phenotype and 
TABLe 2 | Surface marker and transcription factor expression by human group 1 iLCs.
CD56 NKp46 NKp44 CD103 CD49a CD160 CD127 CD11b CD69 CD16 CXCR6 T-bet eomes Reference
Blood cNK (CD56low) + + – – – – – +++ ± +++ – + + (2, 5, 10, 11, 31)
Blood cNK (CD56high) +++ + – – – – + +++ ± – – + + (2, 10, 11, 31)
LP ILC1 – – – – n.d. + + n.d. ± – n.d. ± – (18, 24)
ieILC1 ± + + + + + – – + – + + + (19, 24)
Liver ILC1 +++ + – ± ± n.d. – n.d. + – + + ± (31, 32)
±, heterogenous expression; n.d., not determined.
TABLe 1 | Surface marker and transcription factor expression by murine group 1 iLCs.
NK1.1 NKp46 DX5 TRAiL CD49a CD160 CD127 CD11b CD69 CXCR6 T-bet eomes Reference
Splenic cNK + + + – – – – + – – + + (6, 17, 25, 37, 45, 47, 59)
LP ILC1 + + – n.d. + + + – + ± + – (20, 30, 45, 47)
ieILC1 + + – + + + ± – + ± + + (2, 19, 45, 47)
Liver ILC1 + + – + + + ± – + ± + – (16, 17, 20, 25, 26, 45, 47)
Salivary ILC1 + + + + + n.d. – + + n.d. + + (34, 35, 36)
Uterine ILC1 + + – – + n.d. – n.d. + n.d. + ± (17, 37, 40)
±, heterogenous expression; n.d., not determined.
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developmental origin of ILC1 subsets, as well as their roles during 
antimicrobial immune defense and chronic inflammation.
HeTeROGeNeiTY wiTHiN GROUP 1 
iLCs: LOCATiON, PHeNOTYPe, AND 
FUNCTiONS
The unifying characteristic of group 1 ILCs is their ability to 
produce IFN-γ. Apart from this common attribute, significant 
differences exist between the known ILC1 subsets. The following 
sections summarize the current knowledge of the tissue location, 
surface marker expression, and functional characteristics of the 
main group 1 ILC subsets.
Conventional NK Cells
Conventional NK cells are predominantly found as circulating 
in the blood and within secondary lymphoid tissues such as the 
lymph nodes and spleen. However, cNK cells are also present in 
some non-lymphoid tissues such as the liver and the lung. Resting 
mature cNK cells are identified as CD3ϵ− NK1.1+ NKp46+ DX5 
(CD49b)+ lymphocytes in the mouse (Table  1) and as CD3ϵ− 
CD56+ NKp46+ NKp44− cells in humans (Table 2) (5, 6). Mature 
cNK cells express the transcription factors T-bet and Eomes, 
which are important in mediating their functions. cNK cells can 
be activated through cytokines, such as IL-12, IL-15, and IL-18, 
which induces their secretion of IFN-γ and TNF-α. Furthermore, 
cNK cells are activated through ligation of specific surface recep-
tors. cNK cells express a variety of activating and inhibitory 
NK cell receptors that allow them to differentiate between self 
and non-self and between healthy and infected or malignantly 
transformed cells. Activation of cNK cells through these surface 
receptors typically triggers cytokine production and can induce 
cytotoxicity of target cells via cNK cell release of perforin and 
granzymes. Through these functions, cNK cells fulfill a potent 
pro-inflammatory role during the host–response to microbial 
pathogens. In particular, cNK cell-mediated recognition and 
elimination of altered host cells contributes to antiviral immunity 
and tumor immunosurveillance (6–10). In humans, two main 
cNK cell subsets exist that differ in their phenotype and func-
tions: the majority of blood cNK cells are CD56low and display 
high cytotoxic potential, while the minor CD56high subset of cNK 
cells has low cytotoxic functions but shows potent production 
of inflammatory cytokines (10, 11). In contrast to the peripheral 
blood compartment, CD56high cNK cells represent the major 
cNK cell subset within human secondary lymphoid tissues such 
as lymph nodes, tonsils, and spleen (12). In mice, a subset of 
cNK cells with thymic origin and preferential homing to lymph 
nodes has been identified that may represent the equivalent of 
human CD56high cNK cells (13). The lineage relationships and 
specific functions of these different cNK cell subsets during host–
responses are still being investigated. Blurring the lines between 
innate and adaptive lymphocytes, there is accumulating evidence 
that demonstrates close parallels between cNK cells and adaptive 
lymphocytes. Similar to T cells, cNK cells can undergo an expan-
sion and contraction phase during microbial infections, followed 
by the generation of a pool of memory cells. These memory cNK 
cells possess enhanced cytolytic and cytokine responses during 
secondary exposure to certain microbial pathogens, a finding that 
suggests that immunological memory is not confined to adaptive 
lymphocytes (14).
iLC1s
Unconventional NK cells (ILC1s) are currently defined as tissue-
resident NK-like cells that do not develop from conventional 
NK cell precursors (NKP) and are not typically found in blood 
or lymphoid organs. Subsets of ILC1s have been identified in 
a variety of non-lymphoid tissues, including small intestinal 
mucosa, liver, salivary glands, and the female reproductive tract 
(Tables 1 and 2). In mice, these pools of tissue-resident ILC1s 
do not recirculate and appear to be maintained predominantly 
via local self-renewal rather than through replenishment from 
blood-derived ILC1s or their precursors (15–17). Apart from 
these common attributes, significant differences exist between 
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the individual ILC1 subsets in regards to their phenotype and 
known functions. Furthermore, for some of these subsets, which 
appear to be ILC1s based on their characteristic cytokine produc-
tion, a clear lineage relationship to other ILC1s or cNK cells has 
not firmly been established. For the purpose of this review, I will 
focus on some of the better-characterized members of the ILC1 
lineage, which includes the subsets of ILC1s in the intestine and 
liver.
intestinal iLC1s
Intestinal ILCs that express typical NK cell receptors –NKp46 and 
NK1.1 in the mouse; NKp46 and/or CD56 in humans – have in 
the past collectively been considered as cNK cells due to their NK 
cell-like phenotype and their ability to produce IFN-γ. However, 
evidence is now emerging that the intestinal mucosa contains 
several types of group 1 ILCs that are distinct from cNK cells. Two 
main subsets of intestinal ILC1s were recently identified in mice 
and humans: intraepithelial ILC1s (ieILC1s) and lamina propria-
resident ILC1s (LP ILC1s) (18–20). ieILC1s are found in the 
intestinal epithelium and resemble cNK cells in their expression 
of canonical NK cell receptors. However, unlike resting cNK cells, 
ieILC1s express surface markers typical of intraepithelial T cells, 
such as the integrin CD49a, the activation marker CD69, the 
HVEM receptor CD160, and in humans, the integrin CD103 (19). 
To date, it is unclear whether this surface marker pattern is a result 
of tissue factors encountered in the intestinal epithelium, or is a 
characteristic of a separate lineage of cells. Like cNK cells, ieILC1s 
express the transcription factors T-bet and Eomes; however, stud-
ies in mice provided evidence that ieILC1s do not develop from 
a conventional NKP (discussed below in Section Development). 
Like most other ILC1s, ieILC1s are potent producers of IFN-γ, 
which they release in response to IL-12 and IL-15, and are likely 
to contribute not only to immune protection but also to chronic 
inflammation of the intestinal mucosa.
Murine LP ILC1s share characteristics with cNK cells and 
ieILC1s, including surface expression of NKp46 and NK1.1. 
However, unlike the latter two subsets, mouse LP ILC1s express 
high levels of the IL-7 receptor alpha chain (CD127). Furthermore, 
LP ILC1s are positive for CD27, Thy1, and c-kit, which are not 
typically expressed on mature cNK cells, and they are negative for 
most Ly49 receptors. Unlike cNK cells and ieILC1s, LP ILC1s only 
express T-bet but not Eomes (20). In human intestinal lamina pro-
pria, a CD127+ ILC subset with ILC1-like functions has recently 
been described. These cells lack CD56 and NKp46 but express 
CD161, a marker also found on some human cNK cells, ILC2s, 
and ILC3s (18, 21–23). These ILC1s are Eomes negative; subsets of 
these cells are T-bet positive and produce IFN-γ (18, 24).
Liver iLC1s
The liver contains cNK cells as well as ILC1s, the two of which can 
be distinguished by their different expression of surface markers 
and transcription factors. In mice, liver ILC1s are CD3ϵ− NK1.1+ 
DX5− cells with high expression of both the integrin CD49a 
(VLA-1) and the cytotoxicity-inducing ligand TRAIL. In contrast, 
cNK cells in the liver are DX5+ CD49a− TRAIL−. Both cNK and 
ILC1s in the liver express T-bet; however, like LP ILC1s, liver 
ILC1s do not express Eomes. Originally believed to represent 
immature cNK cells (25), liver-resident ILC1s are now recognized 
as a separate lineage of group 1 ILCs with different progenitor 
origin, cell trafficking, and functional capacities than cNK cells 
(26–28). Liver ILC1s are potent producers not only of IFN-γ but 
also of additional cytokines such as TNF-α, IL-2, and GM-CSF. 
Liver-resident ILC1s lack the typical cytotoxic machinery – per-
forin and granzymes A and B – that are common to cNK cells. 
In contrast, they express high levels of granzyme C and display 
potent TRAIL-mediated cytotoxicity (17, 29, 30). Human liver 
ILC1s have been identified as CD56high CD16− cells capable of pro-
ducing IFN-γ upon activation (31). While the majority of these 
cells are CD49a− Eomes+, a minor subset expresses CD49a+ and 
lacks Eomes, and may thus represent the human counterpart of 
murine liver CD49a+ ILC1s (32). In mice, liver ILC1s are capable 
of generating immunologic memory to haptens and viral antigens 
and are capable of mediating robust recall responses upon rechal-
lenge with the same antigen (16, 33), a feature that has not yet 
been demonstrated for any of the other known ILC1 subsets.
Salivary Gland iLC1s
In mice, a unique subset of NK-like cells resides in salivary glands 
(34–36). While these cells closely resemble cNK cells in both sur-
face receptor and transcription factor expression, they also share 
several features with unconventional NK cells, and in particular, 
with liver ILC1s. Most notably, both salivary gland ILC1s and liver 
ILC1s express TRAIL and CD49a (34, 35). Unlike liver ILC1s; 
however, salivary gland ILC1s express DX5 and Eomes. Salivary 
gland ILC1s are similar to liver ILC1s in their ability to induce 
TRAIL-mediated cytotoxicity; however, in contrast to most other 
ILC1s, salivary gland ILC1s are poor producers of IFN-γ and thus 
do not entirely fit the classical definition of group 1 ILCs (34, 36).
iLC1s in Other Tissues
NK-like cells are also found in other non-lymphoid organs, 
such as the uterus, kidney, and skin of mice and humans (17, 
37–41). These cells vary in their phenotype, transcription factor 
expression, and functions, which may in part be dictated by their 
specific tissue microenvironment. Common features of these 
NK-like cells are their relatively poor cytotoxic potential but 
potent production of cytokines and growth factors. In the preg-
nant uterus, non-classical NK cells are thought to play important 
roles during fetal implantation and vascular remodeling at the 
decidua (40–42). These uterine NK cells share features with cNK 
cells, such as the expression of certain activating and inhibitory 
NK cell receptors, and the expression of perforin and granzymes. 
However, their developmental origin is still debated (40, 41). In 
the uterus of virgin mice, several distinct cell populations with 
NK-like (NK1.1+ NKp46+ T-bet+) phenotype were recently 
described: DX5+ CD49a− cells that likely represent cNK cells as 
well as a DX5− CD49a+ putative ILC1 population that contains 
both Eomes+ and Eomes− subsets (17, 37). Further studies are 
needed to investigate the lineage relationships of these distinct 
uterine group 1 ILC subsets and their individual functions at this 
tissue site. DX5− CD49a+ ILC1s with similarity to liver ILC1s were 
also described in murine skin and kidneys (17, 38). In the murine 
lung, cNK cells have been studied extensively (5); however, it is 
currently unknown whether lung tissue also contains distinct 
FiGURe 1 | Development of iLCs. All ILCs develop from a common lymphoid progenitor (CLP), which differentiate into a committed ILC precursor population 
(αLP). The development of cNK cells then diverges from that of other ILCs: cNK cells arise from an NK cell precursor (NKP), while all other ILCs are formed from a 
common helper innate lymphoid precursor (CHILP) that upon upregulation of the transcription factors Id2, PLZF, and GATA-3 become committed innate lymphoid 
cell precursors (ILCp) and can give rise to ILC1s, as well as to most group 2 and 3 ILCs. Development of mature cNK cells from NKPs is critically dependent on the 
transcription factors Eomes but also involves T-bet, while ILC1 development from ILCp is dependent on T-bet but not Eomes.
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ILC1 subsets. In human lung, a putative ILC1 subset has recently 
been identified (43); however, further studies are required to 
confirm its specific phenotype and to investigate its functions.
iLC Plasticity
Further complicating the identification of ILC1s, a subset of 
group 3 ILCs in murine intestinal tissues, termed NCR+ ILC3s, was 
recently shown to convert to IFN-γ-producing, T-bet-expressing 
cells during microbial infections (20, 21, 44). Conversion of these 
ILC3s is accompanied by their downregulation of their specific 
transcription factor RORγt, resulting in a cell population that 
resembles ILC1s in their phenotype and cellular functions. Due 
to their different lineage relationship compared to ILC1s, these 
converted ILC3s, termed “ex-RORγt ILCs,” are not typically 
regarded as a “true” ILC1 subset. Additional ILC plasticity was 
recently identified for a subset of human tonsil ILC1s, which in 
culture with ILC3-polarizing cytokines acquired RORγt expres-
sion and switched their cytokine profile from predominantly 
IFN-γ to the ILC3-specific cytokine IL-22 (24). This conversion 
was not seen in mice, as LP ILC1s were unable to convert to 
ILC3s; however, “ex-RORγt ILCs” were capable of reverting back 
to RORγt-expressing ILC3s (24).
iLC1 Signature Genes
Transcriptional profiling of ILC1s and cNK cells from liver, small 
intestine, and spleen recently demonstrated that the gene expres-
sion by these tissue ILC1s clearly differs from that of cNK cells. 
Principle-component analysis from this study placed the tested 
ILC1 subsets closer to each other than to cNK cells from the same 
tissues. However, in addition to shared gene signature, each ILC1 
subset possesses a tissue-specific transcriptional signature (45). 
In contrast, liver and spleen cNK cell transcriptional profiles 
were indistinguishable, indicating that cNK cells from different 
tissues represent a relatively homogeneous population. Despite 
the differences between individual ILC1 subsets, common sig-
nature genes were identified that distinguish ILC1s from cNK 
cells; among these are higher transcript levels for CD127, the 
chemokine receptor CXCR6, and, interestingly, for some T cell 
receptor (TCR) chains, although no TCR chain protein expres-
sion was detected either intracellularly or on the cell surface. The 
latter finding is intriguing as it suggests common transcriptional 
programs between ILC1s and T cells.
DeveLOPMeNT
All ILCs develop from a common lymphoid progenitor (CLP), 
which further differentiates into a shared ILC precursor, termed 
α-lymphoid precursor (αLP) (or common ILC progenitor, CILP). 
This shared precursor can be identified by its expression of the 
integrin α4β7 and of CD127. Further differentiation of αLP 
generates at least two different precursors with more restricted 
lineage repopulation capacity: a common helper ILC precursor 
(CHILP) that can give rise to ILC1s and all other ILC subsets 
except cNK cells, and an NKP, which can differentiate into cNK 
cells but no other ILCs (2, 46–48) (Figure 1). Differentiation of 
these precursors from CLP requires the acquisition of the tran-
scription factors Id2, NFIL3, and Tox; mice deficient in any of 
these factors show greatly reduced numbers of all ILCs (49–55). 
Additionally, the Runx family of transcription factors and in 
particular, Runx3 is required for normal development of group 1 
and group 3 ILCs (56, 57). The development of mature ILC1s and 
cNKs from CHILPs and NKP, respectively, depends on a variety 
of additional transcription factors and cytokines, many of which 
have only very recently been elucidated. The following sections 
discuss the individual requirements for the differentiation of cNK 
cells and ILC1s from these early precursors.
5Fuchs ILC1s in Inflammation and Infection
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Development of cNK Cells
Direct precursors to cNK cells (NKP) were originally defined as 
lineage-negative (Lin−) cells that express the IL-2 receptor beta 
chain (CD122) but none of the typical NK cell receptors. This pre-
cursor population, however, was later found to include cells with 
T cell differentiation potential and was subsequently refined to 
include only Lin−CD122+ cells that co-expressed CD244, CD27, 
and CD127. The generation of NKPs from CLPs is dependent 
on the transcription factors NFIL3, Id2, and Tox, which are also 
involved in the development of CHILPs for ILC development 
(1, 2). Unlike other ILCs, however, development of cNK cells 
does not include a precursor that expresses the transcription 
factor PLZF. As recent studies demonstrated, PLZF is specifically 
expressed during ILC differentiation from CHILPs, allowing a 
further refinement of the differences between NKP and ILC1 
precursors. PLZF lineage-tracing experiments revealed that true 
NKPs have the phenotype Lin−CD122+CD244+CD27+CD127+PL
ZF−α4β7−, while ILC1 precursors are characterized by additional 
expression of PLZF and α4β7 (58).
Further differentiation of NKPs gives rise to immature cNK 
cells, a process that is accompanied by gradual acquisition of the 
NK cell receptors NK1.1 and NKp46 and the transcription fac-
tors T-bet and Eomes. Immature cNK cells can be identified as 
DX5− CD27+ CD11b− cells, which are T-bet+ but Eomes− (23, 25, 
59). With these marker characteristics, immature cNK cells have 
striking similarity to ILC1s, making it difficult to differentiate 
between the two populations. Maturation of cNK cells is depend-
ent on the cytokine IL-15 and is accompanied by the acquisition 
of DX5, upregulation of CD11b, and loss of CD27 expression. The 
cytokine IL-7, which is crucial for the development of group 2 
and 3 ILCs, is not required for mature cNK cell or ILC1 develop-
ment (20, 26, 51). cNK cell maturation is dependent on Eomes 
and T-bet, as mature cNK cells are absent in Eomes-deficient 
mice and reduced in numbers and with less mature phenotype in 
T-bet-deficient mice (25, 60).
Development of iLC1s
It has been proposed that ILC1s, like group 2 and 3 ILCs, develop 
from a CHILP that further differentiates into an ILC precursor 
(ILCp) in a PLZF-dependent process (48, 58). Lineage tracing 
for PLZF expression revealed that all ILCs, with the exception of 
cNK cells and a subset of ILC3s (LTi-like ILC3s), develop from 
a PLZF-positive precursor (48). Among the investigated group 1 
ILCs, liver ILC1s and intestinal ieILC1s, but not splenic or liver 
cNK cells, were lineage traced for PLZF expression, and thus, 
the former two are likely to arise from the same ILC precursor 
(48). Other ILC1s such as LP ILC1s or salivary gland ILC1s were 
not interrogated in this study (48). Interestingly, PLZF-deficient 
bone marrow can still generate normal numbers of ieILC1s (48), 
indicating the existence of alternative pathways for ILC1 differen-
tiation, which may involve branching from either PLZF− CHILP 
or NKP. Within ILCp, the highest ILC1-generating capacity was 
found in a CD122+ subset that lacks the chemokine receptor 
CXCR5, suggesting that these CD122+ CXCR5+ ILCp may rep-
resent the direct precursors to ILC1s (61).
Differentiation of liver ILC1s and intestinal ILC1s (both LP 
ILC1s and ieILC1s) further depends on the transcription factor 
T-bet (17, 19, 20, 25, 62). In contrast to cNK cells, which require 
Eomes for their final maturation, liver ILC1s and presumably all 
other Eomes− ILC1s develop independently of this transcription 
factor (25). Interestingly, there is remarkable diversity among 
ILC1 subsets in relation to their dependence on other transcrip-
tion factors and cytokines. Although NFIL3 is required for the 
development of most group 1, 2, and 3 ILCs, including cNK cells 
and intestinal ieILC1s, mice deficient in this transcription factor 
have normal numbers of salivary gland, uterine, and kidney-
resident ILC1s (17, 34, 38). In regards to liver ILC1s, the precise 
role of NFIL3 remains to be determined, as currently conflicting 
data exists showing either dependence (49, 55) or independence 
of liver ILC1s on this transcription factor (17, 63). Similarly, 
dependence on the transcription factor GATA-3 appears to vary 
between the individual ILC1 subsets. GATA-3 deficiency severely 
reduces numbers of intestinal LP ILC1s but has no effect on ieILC1 
or cNK cell numbers (64). As development of all CD127+ group 2 
and group 3 ILCs is dependent on GATA-3, it has been suggested 
that only CD127+ ILC1s but not CD127− ILC1s require GATA-3 
for their development (20, 64).
Development of most group 1 ILCs, including cNK cells, 
is dependent on the cytokine IL-15. We recently found that in 
contrast to all other ILC1s, intestinal ieILC1s were only partially 
dependent on IL-15, as their numbers were reduced but not 
absent in mice deficient in the IL-15 receptor alpha chain (19). 
Although some ILC1 subsets express the IL-7 receptor CD127, 
IL-7 appears dispensable for ILC1 development, as mice deficient 
in IL-7 or its receptor CD127 have normal numbers of intestinal 
LP and liver ILC1s (20, 26, 51).
The differences in transcription factor and cytokine require-
ments within ILC1s may be a result of different lineage rela-
tionships between these individual subsets. Further studies are 
needed to identify the individual precursors and their location 
(bone marrow vs. development in peripheral tissues) for each of 
these ILC1 subsets and elucidate potential pathways of conver-
sion within group 1 ILCs and potentially between other ILCs.
iLC1s iN ANTiMiCROBiAL ReSPONSeS
The prototypic function of group 1 ILCs is potent expression 
of IFN-γ upon activation with cytokines or surface receptor 
crosslinking. IFN-γ plays important roles in the immune defense 
to intracellular pathogens, and cNK cells have been recognized 
for their critical functions in the immune defense against a 
variety of viral and bacterial pathogens (7, 9). In most of these 
studies, all cells with NK-like surface phenotype and ability 
for IFN-γ production were regarded as cNK cells. However, it 
appears likely that in some of the earlier studies, ILC1s may have 
contributed to IFN-γ production but were not recognized as a 
separate lineage. Thus, specific roles of ILC1s, as compared to 
cNK cells, during immune defenses to pathogens are only now 
being investigated.
The identification of specific markers for ILC1s, such as CD49a 
expression in liver or expression of CD127 and lack of Eomes in 
LP ILC1s, has made it possible to more accurately assess specific 
host protective roles of ILC1s compared to cNK cells. However, as 
marker expression can change during cellular activation, results 
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still need to be interpreted with caution. Recent studies have 
focused on the potential roles of intestinal ILC1s during  protective 
responses to intestinal pathogens. New findings in this respect 
suggest that following oral infection of mice with the intracel-
lular pathogen Toxoplasma gondii, ILC1s produce the majority of 
IFN-γ, as well as TNF-α, while cNK cells and ILC3s contribute to 
a lesser extent (20). In this particular infection model, Diefenbach 
and colleagues identified ILC1s as the cell type responsible for 
controlling infection, which they accomplish by their rapid 
attraction of inflammatory monocytes to the site of infection. 
Unfortunately, due to the lack of specific ILC1-knockout mice or 
depleting antibodies, it is currently impossible to unequivocally 
attribute a particular function to either ILC1s or cNK cells. In the 
mentioned study on host responses to T. gondii, Diefenbach and 
colleagues examined T-bet-deficient mice, which completely lack 
ILC1s but have cNK cells (although in reduced numbers), as a 
tool to confirm a crucial role of ILC1s during T. gondii infection. 
However, it should be noted that T-bet also plays roles in cNK 
cell maturation and IFN-γ production (60); thus, the failure of 
T-bet-deficient mice to control parasite burden may still partially 
be due to defects in cNK cell functions. Additionally, T-bet is also 
required for the development of NCR+ ILC3s and their conver-
sion into IFN-γ-producing cells (65).
During acute infection with the intestinal pathogen Clostridium 
difficile, ILC1s represent the major innate cell subset to respond 
with IFN-γ production in the LP, epithelium, and MLN of 
infected mice (66). Consistent with this finding, Pamer and col-
leagues further demonstrated that mice lacking ILC1s as well as 
mice deficient in IFN-γ were more susceptible to lethal C. difficile 
infection. For this study, T-bet-deficient mice on a Rag-deficient 
background were used to deduct a specific role for ILC1s during 
the immune defense, and adoptive transfer of T-bet+ CD127+ 
LP ILC1s to these mice imparted partial protection from lethal 
infection. However, as ILC1 transfer only provided partial rescue, 
the authors speculate that the contribution of other innate cells, 
such as cNK cells, neutrophils and monocytes, is likely required 
for protective IFN-γ responses to C. difficile (66).
IFN-γ is also a major factor in the immune defense to intes-
tinal infections with Salmonella enterica serovar Typhimurium. 
A recent study demonstrated that a group of lamina propria 
ILCs was shown to provide the majority of IFN-γ during acute 
infection. However, in this study, it was concluded that converted 
ILC3s, rather than true ILC1s, were responsible for the majority 
of the produced IFN-γ (65). As illustrated in the examples above, 
there is emerging evidence that intestinal ILC1s contribute to the 
immune defense to microbial pathogens. However, to date, an 
accurate assessment of the individual roles of ILC1s, cNK cells, 
and converted ILC3 remains impossible. Further exploration 
of novel markers and transcription factors involved in ILC1 
development and functions may aid in further elucidating their 
specific roles during host protective responses.
iLC1s iN TiSSUe iNFLAMMATiON 
AND AUTOiMMUNiTY
The production of pro-inflammatory cytokines by group 1 ILCs 
has important functions during antimicrobial immune responses. 
However, exaggerated or prolonged cytokine responses can also 
lead to chronic inflammation and autoimmunity. Several studies 
demonstrated that inflamed intestinal tissues from patients with 
Crohn’s disease harbor larger numbers of ILC1s, suggesting a 
role for ILC1s in inflammatory pathology (18, 19). We recently 
investigated the role of ILC1s in a mouse model of colitis induced 
by anti-CD40 injection into Rag-deficient mice. In this model, 
IFN-γ is known as the major factor driving wasting disease 
and systemic inflammation (67). We find that in this model 
of inflammatory bowel disease, intestinal ieILC1s contribute 
to intestinal pathology through production of IFN-γ (19). 
Similarly, mice with a human immune system show accumula-
tion of IFN-γ-producing human ILC1s in the inflamed intestine 
upon challenge with the colitis-inducing agent dextran sodium 
sulfate (18, 19).
A recent study by Victorino et  al. demonstrated that ILC1s 
 contribute to organ dysfunction seen in a mouse model of 
ischemic kidney injury. The authors of this study identified 
NK1.1+ non-T cells as the major culprit that mediate kidney dys-
function following ischemia–reperfusion injury, and found that 
depletion with anti-NK1.1, which depletes both cNK cells and 
ILC1s in kidneys, ameliorated disease, whereas anti-asialo-GM1 
treatment, which preferentially depletes cNK cells, did not protect 
from disease (38). The exact mechanism for this ILC1-mediated 
tissue damage awaits further investigation.
In contrast to the potential detrimental roles of ILC1s 
described above, ILC1s in the salivary gland appear to play 
tissue-protective functions during chronic infection. ILC1s at this 
tissue site show low ability for IFN-γ production; however, they 
can induce cytotoxicity through their expression of TRAIL. Two 
recent studies demonstrated that during chronic infection with 
murine cytomegalovirus, ILC1s protected from autoimmunity 
by regulating both innate and adaptive immune responses in 
the salivary gland. In these studies, salivary gland NK1.1+ cells 
were shown to preserve gland functions by limiting eosinophil 
infiltration and by preventing T cell-mediated autoimmunity 
through TRAIL-mediated cytotoxicity toward activated CD4 
T cells (35, 68). Although individual roles of cNK cells vs. ILC1s 
were not investigated in these studies, a contribution of salivary 
gland-resident ILC1s appears likely, in particular in relation to 
the observed TRAIL-mediated regulatory roles.
OPeN QUeSTiONS
The ILC1 field is still in its infancy, and many questions remain 
as to their specific developmental pathways, and to the lineage 
relationship between the to-date characterized ILC1s subsets. 
For instance, the exact molecular processes that mediate line-
age specification of ILC1 vs. cNK cells during the branch point 
from αLP to either CHILP or NKP are insufficiently understood. 
Furthermore, for several of the putative ILC1 subsets, a lineage 
relationship to ILC1s awaits confirmation. Examples of those 
subsets include salivary gland ILC1s, uterine ILCs, and subsets of 
dermal ILCs. Additional NK-like cells with non-typical pheno-
type and functions have been described, such as CD127+ blood 
and splenic ILC1s and GATA-3-dependent thymic NK cells (13, 
45, 69, 70).
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Furthermore, to date, the extent of ILC plasticity is not clear. 
As discussed above, ILC3s can convert to ILC1-like cells during 
inflammatory conditions. A recent study now also provided evi-
dence that a subset of human ILC1s can gain ILC3-like phenotype 
and function (24). Further studies will be required to define 
whether this ILC1 subset represents a precursor population 
that differentiates into ILC3s, or a mature ILC1 population that 
undergoes conversion to ILC3s, and to investigate the mechanism 
and functional relevance of this ILC1 to ILC3 conversion.
The roles of ILC1s vs. cNK cells during protective host 
responses and chronic inflammation are only now starting to 
being investigated and there is little evidence of their beneficial 
or pathogenic functions during these processes. Group 2 and 3 
ILCs play important roles both as initiators of local inflamma-
tion, as well as in the resolution of inflammation and restoration 
of tissue integrity (71). Further studies are needed to elucidate 
the specific contributions of ILC1s in these processes, and to 
investigate potential crosstalk between ILC1s with other ILCs and 
with adaptive immune cells during the initiation and resolution 
of inflammation.
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